Nov 05, 2024 / 09:00AM GMT
Britt Meelby Jensen Ambu A/S-CEO
Hello everyone and welcome to this call where we from Amber will present our Q4 and full year results from our fiscal year 2,324.
The agenda for today is that we will first present our results on the business and the financials and then we will hand over to the operator to moderate the Q&A session.
I'm Breg Milian and I'm the CEO of Ambu. And with me today, I have Henrik Sbender, our CFO.
So let's dive into the results from our Q4 and the full year in Q4, we delivered 10.6% revenue growth split into 4.5% growth in organic revenue growth in endoscopy and 4.3% in anesthesia and patient monitoring.
In terms of profitability, we had an ebit margin also amounting to 10.6%. And then we had a positive cash flow of DKK98 million for the full year. This means that in terms of revenue growth, we delivered 13.8% and this was mainly driven by endoscopy where we grew 19.7%.
So this strong performance comes after a year where we have had a lot of momentum in the business at Ambu. And where I'm grateful for the
Q4 2024 Ambu A/S Earnings Call Transcript
Nov 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers